Recent Updates
Recently added Catalysts
TNDM Positive Sentiment

Tandem Diabetes Care Announces Third Quarter 2026 Financial Results

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Tandem Diabetes Care reported strong financial results for Q3 2026, with worldwide sales of $283.7 million. The U.S. contributed $191.0 million to this total. The company also noted a gross margin increase of 270 basis points compared to the previous year, alongside pump shipments of around 33,000 units.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sales reached $283.7 million worldwide.
  • Gross margin improved by 270 basis points.
  • Pump shipments totaled approximately 33,000 units.

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Sales of $283.7 million worldwide, including $191.0 million in the United States (U.S.) Gross margin of 57%, up 270 basis points compared to third quarter 2025 Pump shipments of approximately 33,000 worldwide, including nearly 23,000 pu

Frequently Asked Questions

What were Tandem's sales for Q3 2026?

Tandem Diabetes Care reported sales of $283.7 million.

How much did Tandem earn in the U.S. for Q3 2026?

The U.S. contributed $191.0 million to the sales total.

What was the gross margin for Q3 2026?

The gross margin was 57%, up 270 basis points from last year.

How many pumps did Tandem ship in Q3 2026?

Tandem shipped approximately 33,000 pumps worldwide.

ShareAdd on Google
Tags: TNDM Tandem Diabetes Care financial results insulin delivery diabetes technology
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$443M liquidity · $0M/mo burn
~1623 mo
Minimal dilution risk